Driss Berdaï

Dr Driss BERDAI, MD, MScDriss Berdaï is involved in Clinical Pharmacology having more than twenty years of academic, regulatory and industrial experience. He is former Head of the Clinical Trials Unit of the French Medicines Agency (ANSM) and Scientific Administrator (scientific advice, orphan drugs, pharmacovigilance) at the European Medicines Agency (EMA, London). He has served Pfizer as Director-Pharmacovigilance and Pharmacoepidemiology. He has been former medical advisor at the French National Health Fund (CNAM-TS).

Presently he is working as a senior consultant in the Departement of Pharmacology, University Hospital of Bordeaux, France. He is also member of the Transparency Committee of the French HTA body, Haute Autorité de Santé (HAS)

www.has-sante.fr

 
 
The voice of rare disease patients in EuropeEURORDIS The international voice of people living with rare diseasesRare Disease International Bringing together patients, families and experts to share experiences in a moderated multi-language forum. RareConnect The Rare Barometer Programme is a EURORDIS initiative that carries out surveys to transform rare disease patients' experiences into figures and facts that can be shared with decision-makers.Rare Barometer An international awareness raising campaign taking place on the last day of February each year, Rare Disease Day is a EURORDIS initiativeRare Disease Day Join the largest gathering of rare disease stakeholders across Europe, at the biennial European Conference on Rare Diseases and Orphan Products. ECRD is a EURORDIS initiativeEuropean Conference on Rare Diseases